

μ dialysis



Microdialysis Analyzer

Tomorrow Today

When using microdialysis you can foresee what will later become the clinical signs, it creates possibilities for early treatment, that's what we at M Dialysis consider *"Tomorrow Today"*.

Microdialysis also generates unique additional information, beneficial for understanding the patient's current situation.

The benefit of monitoring tissue chemistry is to detect pathological events before they manifest themselves as clinical signs. This offers an opportunity to start treatment hours or even days earlier than when relying on clinical signs only.




Microdialysis - Reinvented

Microdialysis data are now provided in real time, continuously. The values are displayed, both numerically and graphically like curves, to simplify the interpretation. The system is completely automated and can run up to five days without any manual interruption.

The unique MD system continuously monitors the tissue or blood metabolism. It is developed for routine use in Critical Care patients in the Intensive Care Unit.

The MD system offers

- Continuous monitoring of Glucose, Lactate and Pyruvate
- Easy to use and robust for up to
 5 days continuous monitoring
- \checkmark Automated, plug and play system



Catheter flow pattern

The basics of microdialysis


The Microdialysis principle allows molecules from the tissue or blood to pass via diffusion to the perfusion fluid inside the Microdialysis catheter's membrane. The perfusion fluid then transports the molecules to a biosensor in the MD System that continuously measures the concentration of Glucose, Lactate and Pyruvate.

Glucose, Lactate and Pyruvate are markers for ischemia, mitochondrial dysfunction, hypoxia and hypoglycemia in tissue and in blood.

As an example; within Neuromonitoring it has been shown that an increase of the Lactate Pyruvate ratio (LP-ratio) in the presence of low Pyruvate indicates brain tissue ischemia and an increase in LP-ratio with normal or slightly increase of Pyruvate indicates mitochondrial dysfunction.

References: Techniques and strategies in Neurocritical care originating from southern Scandinavia, Nordström et al J Rehabil Med 2013; 45: 710-717

Consensus statement from the 2014 International Microdialysis Forum. Hutchinson PJ et al. Intensive Care Med. 2015 Sep;41(9):1517-28




L dialysis

M Dialysis is world leading in providing microdialysis products for the health care sector.

We collaborate with clinicians and researchers for improvements of the technology, finding new ways of using Microdialysis with focus on patient benefit.

Our vision is to take microdialysis to its fullest potential within a wide range of applications and make it accessible.





M Dialysis AB

Box 5049 SE-121 05, Stockholm Sweden

E-MAILinfo@mdialysis.sePHONE+46-8-4701020WEBSITEwww.mdialysis.com